A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.
about
Lymphoma: immune evasion strategiesDurable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group.Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphomaLymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP).Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.Fool's gold, lost treasures, and the randomized clinical trial.Immunogenicity of an inactivated monovalent 2009 influenza A (H1N1) vaccine in patients who have cancerA phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer.Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model.Angiogenesis in nodal B cell lymphomas: a high throughput study.A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.The role of angiogenesis in human non-Hodgkin lymphomas.Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphomaTargeting angiogenesis: a novel, rational therapeutic approach for non-Hodgkin lymphoma.Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma.Emerging therapies for B-cell non-Hodgkin lymphoma.Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies.Prognostication of diffuse large B-cell lymphoma in the rituximab era.Novel agents for diffuse large B-cell lymphoma.New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practicePharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity.The role of targeted therapy and biomarkers in breast cancer treatment.Targeting the vascular endothelial growth factor in hematologic malignancies.Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma.VEGF overexpression is a valuable prognostic factor for non-Hodgkin's lymphoma evidence from a systemic meta-analysis.Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.Prognostic significance of immunohistochemical expression of the angiogenic molecules vascular endothelial growth factor-A, vascular endothelial growth factor receptor-1 and vascular endothelial growth factor receptor-2 in patients with classical HoHistiocytic sarcoma - targeted therapy: novel therapeutic options? A series of 4 cases.Pretreatment levels of vascular endothelial growth factor in plasma predict a complete remission rate and time to relapse or progression in patients with diffuse large B-cell lymphoma.The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma.Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab.An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma.
P2860
Q28080705-57AE58E6-BA64-4E5F-84D5-51AF8A520417Q33388648-8B28C9B7-A468-4AF3-A82E-3F815C0399F3Q33394774-DB1F23A6-17E7-437C-B25A-EA4F50FE7A9DQ33406444-0C368422-6948-46C9-9E70-B1233D7357E4Q33601693-3A1610F3-5627-443A-B646-09714CB4CE8CQ33692555-BC60F796-032F-4626-8B3A-15D37C59F656Q33874179-D4AC5703-22F5-4015-BBEB-DCD89C7FB8B3Q33978922-206FB146-85C5-4088-9125-4B5EB5E1865EQ34042407-C08E1B6F-F620-4E7A-A34D-E4A162B466E7Q34669260-277E594D-E890-4823-837E-00F2AFBC5D1AQ35705166-814810F8-8E8C-44CF-968C-DE81A8EB9509Q35928913-0A70AA3A-40C1-4389-86D5-8CC0E349EB37Q35941562-E0C0F561-0049-4D8C-93C3-245EE464BD27Q36014424-1D87C3AB-5951-4319-B734-F4A1A8255484Q36163040-0D4F9566-71C9-46F1-9C1A-E6D5A20E83AFQ36301590-F7F524F9-FE18-4DA7-9293-1E604330A2B0Q36670881-70E7FC81-F5CF-405D-919D-F9DD77DD0B96Q36962682-4E6F1974-0EE5-438F-9353-D3FAC2AC7416Q37321798-31EF7EB9-0A51-4C0A-B5A0-7CF174EF6174Q37487754-5735EE43-3F0C-4A92-BB6B-07A86EF10FD2Q37501114-1FCAE60F-C623-4294-9A1D-1BC6189BAC33Q37598947-2A5A54A4-D902-4ACA-B8AE-F208D275AEF6Q37766891-7F090B73-314D-42AE-94DF-74D86BD4F5D7Q37773249-9304FE6F-2393-4CA9-BE8F-32ED7F903626Q37833087-DBE7A385-4C74-4155-9C5B-9F3E5ED31916Q37858532-0F968B56-8FA7-4C9A-AB85-BC7C2174AE62Q37918027-81AABFC7-4BB2-454B-A178-7CB2AD39678EQ37929798-7EBCE993-20B5-4707-BC42-C56B99EE6AA1Q37938966-E47C010C-2AC1-4F38-A79D-F622EEBF4C58Q38018259-9F068ED0-F41E-4D00-88A2-DF429E3244B1Q38038645-179EAA66-E9D0-4DCB-82E9-86AA11DF391EQ38311896-F660AF08-603C-445C-A774-DAD4F664EC6BQ38391574-87672F41-42CC-4209-8CAF-0F6AF87465D4Q39045701-DDBE3FA9-A8AC-43F8-96E1-9C68F5386FC2Q43883383-A86BEF03-5E82-4B30-B851-7C9DC743461BQ44720968-EAF0CD5C-5E2A-442E-B605-07EC0A607154Q45849297-A051BD69-BE1D-4F38-9622-90ABB8E1D70CQ47563526-286D26A2-80A1-4CC4-8993-7890DC26FD3CQ50503410-0859B3B4-3201-42F6-B85C-10AC2CBC3FF0Q52584351-38F5F3BE-30E0-4A1F-8F30-4B822A6BB3E1
P2860
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
A phase II trial of single age ...... st oncology group study S0108.
@ast
A phase II trial of single age ...... st oncology group study S0108.
@en
type
label
A phase II trial of single age ...... st oncology group study S0108.
@ast
A phase II trial of single age ...... st oncology group study S0108.
@en
prefLabel
A phase II trial of single age ...... st oncology group study S0108.
@ast
A phase II trial of single age ...... st oncology group study S0108.
@en
P2093
P2860
P1433
P1476
A phase II trial of single age ...... st oncology group study S0108.
@en
P2093
Alison T Stopeck
Daniel O Persky
Joseph M Unger
Lisa M Rimsza
Maria Iannone
Michael Leblanc
Richard I Fisher
Thomas P Miller
William T Bellamy
P2860
P304
P356
10.1080/10428190902856808
P577
2009-05-01T00:00:00Z